drugset / Trial / NCT04088149
An Open-labeled Phase II Study to Evaluate the Efficacy and Safety of GXNPC-1 in Patients with Chronic Stroke
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the efficacy for subjects with chronic stroke after GXNPC-1 injection.
Timeline
- Start
- 2020-02-06
- Primary completion
- 2023-08-15
- Completion
- 2024-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GXNPC1 | Cell therapy | 1e+08 cells | — |
| Subject | GXNPC1 | Cell therapy | 2e+08 cells | — |